Why Novavax Stock Is Tumbling Today

61
4
Favorite

Why Novavax Stock Is Tumbling Today

Motley Fool2022-01-14

What happenedShares of vaccine specialist Novavax appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（4）

PatWong
·2022-01-15
Sell
Reply
Like
Report
Felixmc9999
·2022-01-15
Half of my portfolio is holding novavax shares now
Reply
Like
Report
SSSG
·2022-01-14
Noted
Reply
1
Report
来人
·2022-01-14
😭
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2203712234?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-14 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2203712234","market":"us","top_or_hot":-1,"title":"Why Novavax Stock Is Tumbling Today","media":"Motley Fool","content":"<div>\n<p>What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 22:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/","article_id":"2203712234","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2203712234","pubTimestamp":1642169014,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Concerns about the sustainability of the COVID-19 vaccine market are weighing on the biotech's shares today.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NVAX":"诺瓦瓦克斯医药","BK4568":"美国抗疫概念"},"translate_title":"为什么诺瓦瓦克斯医药股市今天暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move lower holds, Novavax's shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.So whatIn recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron's highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.Although this scenario won't necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax's stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.Now whatShould bargain hunters take advantage of Novavax's falling share price? That's a hard question to answer right now. Novavax's stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9005191929,"gmtCreate":1642203422955,"gmtModify":1676533691245,"author":{"id":"4092487035590380","authorId":"4092487035590380","name":"PatWong","avatar":"https://static.tigerbbs.com/6d2db4fdb2321496faf7af320ac6557d","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4092487035590380","authorIdStr":"4092487035590380"},"htmlText":"Sell","listText":"Sell","text":"Sell","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005191929","repostId":2203712234,"repostType":4,"repost":{"id":"2203712234","pubTimestamp":1642169014,"share":"https://ttm.financial/m/news/2203712234?lang=&edition=fundamental","pubTime":"2022-01-14 22:03","market":"us","language":"en","title":"Why Novavax Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2203712234","media":"Motley Fool","summary":"Concerns about the sustainability of the COVID-19 vaccine market are weighing on the biotech's shares today.","content":"<html><head></head><body><h2>What happened</h2><p>Shares of vaccine specialist <a href=\"https://laohu8.com/S/NVAX\"><b>Novavax</b> </a> appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax&#39;s shares fell by as much as 10.9%.</p><p>If this latest move lower holds, Novavax&#39;s shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.</p><h2>So what</h2><p>In recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron&#39;s highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.</p><p>Although this scenario won&#39;t necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax&#39;s stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.</p><h2>Now what</h2><p>Should bargain hunters take advantage of Novavax&#39;s falling share price? That&#39;s a hard question to answer right now. Novavax&#39;s stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 22:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BK4139":"生物科技","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203712234","content_text":"What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move lower holds, Novavax's shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.So whatIn recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron's highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.Although this scenario won't necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax's stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.Now whatShould bargain hunters take advantage of Novavax's falling share price? That's a hard question to answer right now. Novavax's stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005327884,"gmtCreate":1642180150810,"gmtModify":1676533690068,"author":{"id":"4097752709229510","authorId":"4097752709229510","name":"Felixmc9999","avatar":"https://static.tigerbbs.com/3bb594e293cdff97b357441dc2a49ebc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4097752709229510","authorIdStr":"4097752709229510"},"htmlText":"Half of my portfolio is holding novavax shares now","listText":"Half of my portfolio is holding novavax shares now","text":"Half of my portfolio is holding novavax shares now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005327884","repostId":2203712234,"repostType":2,"repost":{"id":"2203712234","pubTimestamp":1642169014,"share":"https://ttm.financial/m/news/2203712234?lang=&edition=fundamental","pubTime":"2022-01-14 22:03","market":"us","language":"en","title":"Why Novavax Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2203712234","media":"Motley Fool","summary":"Concerns about the sustainability of the COVID-19 vaccine market are weighing on the biotech's shares today.","content":"<html><head></head><body><h2>What happened</h2><p>Shares of vaccine specialist <a href=\"https://laohu8.com/S/NVAX\"><b>Novavax</b> </a> appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax&#39;s shares fell by as much as 10.9%.</p><p>If this latest move lower holds, Novavax&#39;s shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.</p><h2>So what</h2><p>In recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron&#39;s highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.</p><p>Although this scenario won&#39;t necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax&#39;s stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.</p><h2>Now what</h2><p>Should bargain hunters take advantage of Novavax&#39;s falling share price? That&#39;s a hard question to answer right now. Novavax&#39;s stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 22:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BK4139":"生物科技","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203712234","content_text":"What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move lower holds, Novavax's shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.So whatIn recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron's highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.Although this scenario won't necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax's stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.Now whatShould bargain hunters take advantage of Novavax's falling share price? That's a hard question to answer right now. Novavax's stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005333591,"gmtCreate":1642170212833,"gmtModify":1676533688659,"author":{"id":"3571092559413416","authorId":"3571092559413416","name":"SSSG","avatar":"https://static.tigerbbs.com/8b6004ac9552e20472bc1792d3c17df6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571092559413416","authorIdStr":"3571092559413416"},"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005333591","repostId":2203712234,"repostType":4,"repost":{"id":"2203712234","pubTimestamp":1642169014,"share":"https://ttm.financial/m/news/2203712234?lang=&edition=fundamental","pubTime":"2022-01-14 22:03","market":"us","language":"en","title":"Why Novavax Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2203712234","media":"Motley Fool","summary":"Concerns about the sustainability of the COVID-19 vaccine market are weighing on the biotech's shares today.","content":"<html><head></head><body><h2>What happened</h2><p>Shares of vaccine specialist <a href=\"https://laohu8.com/S/NVAX\"><b>Novavax</b> </a> appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax&#39;s shares fell by as much as 10.9%.</p><p>If this latest move lower holds, Novavax&#39;s shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.</p><h2>So what</h2><p>In recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron&#39;s highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.</p><p>Although this scenario won&#39;t necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax&#39;s stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.</p><h2>Now what</h2><p>Should bargain hunters take advantage of Novavax&#39;s falling share price? That&#39;s a hard question to answer right now. Novavax&#39;s stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 22:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BK4139":"生物科技","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203712234","content_text":"What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move lower holds, Novavax's shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.So whatIn recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron's highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.Although this scenario won't necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax's stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.Now whatShould bargain hunters take advantage of Novavax's falling share price? That's a hard question to answer right now. Novavax's stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005330173,"gmtCreate":1642169683827,"gmtModify":1676533688643,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3575544575320394","authorIdStr":"3575544575320394"},"htmlText":"😭","listText":"😭","text":"😭","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005330173","repostId":2203712234,"repostType":2,"repost":{"id":"2203712234","pubTimestamp":1642169014,"share":"https://ttm.financial/m/news/2203712234?lang=&edition=fundamental","pubTime":"2022-01-14 22:03","market":"us","language":"en","title":"Why Novavax Stock Is Tumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2203712234","media":"Motley Fool","summary":"Concerns about the sustainability of the COVID-19 vaccine market are weighing on the biotech's shares today.","content":"<html><head></head><body><h2>What happened</h2><p>Shares of vaccine specialist <a href=\"https://laohu8.com/S/NVAX\"><b>Novavax</b> </a> appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax&#39;s shares fell by as much as 10.9%.</p><p>If this latest move lower holds, Novavax&#39;s shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.</p><h2>So what</h2><p>In recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron&#39;s highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.</p><p>Although this scenario won&#39;t necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax&#39;s stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.</p><h2>Now what</h2><p>Should bargain hunters take advantage of Novavax&#39;s falling share price? That&#39;s a hard question to answer right now. Novavax&#39;s stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Tumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Tumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 22:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BK4139":"生物科技","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2022/01/14/why-novavax-stock-is-tumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203712234","content_text":"What happenedShares of vaccine specialist Novavax  appear to be in for another tough session today. Ahead of the opening bell Friday, Novavax's shares fell by as much as 10.9%.If this latest move lower holds, Novavax's shares will have lost over a third of their value in just the past 30 days. Investors have been backing away from this former high-flying biotech stock in response to the unique characteristics displayed by the omicron variant.So whatIn recent weeks, some top immunologists have started to float the idea that the omicron variant may be the last gasp of the pandemic. Due to omicron's highly infectious nature, it could bring about the end to the acute phase of the pandemic by broadening natural immunity across the global population and providing a wider barrier of immune protection against the next variant of concern.Although this scenario won't necessarily impact the near-term sales of vaccine companies like Novavax that already have worldwide supply contracts in place, it would likely reduce the demand for COVID-19 vaccines in 2023 and beyond. Based on how Novavax's stock has been acting over the past four weeks, the market appears to be taking this growing possibility to heart.Now whatShould bargain hunters take advantage of Novavax's falling share price? That's a hard question to answer right now. Novavax's stock certainly could rally in a big way if the company lands an Emergency Use Authorization from the Food and Drug Administration soon. Then again, it is impossible to predict how this vaccine stock will react to positive news in the midst of an exceedingly harsh bear market for biotechs.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":61,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}